You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(06160.HK)與諾華達成合作開發及商業化替雷利珠單抗
阿思達克 01-12 08:53
百濟神州(06160.HK)宣布,旗下間接全資子公司與Novartis Pharma(諾華)就授權諾華在多個國家開發、生產和商業化百濟神州的抗PD-1抗體百澤安(替雷利珠單抗)達成合作與授權協議,授權區域包括美國、加拿大、墨西哥、歐盟成員國、英國、挪威、瑞士、冰島、列支敦士登、俄羅斯和日本。

根據合作與授權協議,百濟神州將獲得諾華6.5億美元的預付款,並在達到藥政里程碑事件之後有資格獲得至多13億美元的里程碑付款,在達到銷售里程碑事件之後有資格獲得至多2.5億美元的里程碑付款,另有資格獲得百澤安授權區域未來年度淨銷售額的近20%至近30%的分級特許使用費,但在特定情況下會合理相應減少。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account